Oral Film Composition for Precise Active Dissolution Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral film dosage forms face challenges in precise active dissolution testing, particularly for rapid-dissolving products, due to the need for improved dissolution testing methods that provide precise measurements at small time intervals and ensure consistent drug absorption.
Innovation Solution
Development of an oral film with a water-soluble or water-swellable polymer matrix, containing actives with an average particle size D90 of less than 160 microns, and additives, using PION technology for precise dissolution testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional dissolution testing methods are used for rapid-dissolving oral films, then the testing process is simpler, but the measurement precision and ability to capture rapid dissolution profiles deteriorates
Solution Approach 1:
The patent replaces traditional mechanical/manual dissolution testing methods with PION (Phosphorescence Imaging Optical Sensor) technology that uses optical fields and phosphorescent sensors to detect and measure active ingredient dissolution. This substitution enables precise, automated measurement of rapid dissolution profiles without manual intervention, resolving the contradiction between measurement precision and method complexity.
2Productivity
If oral films are designed to dissolve rapidly, then patient compliance and drug absorption improve, but the ability to obtain precise dissolution data at small time intervals deteriorates
Solution Approach 1:
The patent incorporates phosphorescent markers or uses the inherent phosphorescence of the active ingredient or excipients into the oral film formulation before dissolution testing. This preliminary incorporation of the sensing mechanism allows the system to automatically detect and record dissolution at multiple precise time intervals as the film dissolves rapidly in the patient's mouth, capturing the complete dissolution profile without requiring complex external measurement equipment during the actual dissolution process.
3Ease of operation
If tablet size is reduced to improve swallowability, then ease of ingestion improves, but manufacturing precision and dosing accuracy deteriorates
Solution Approach 1:
The patent transitions from traditional rigid tablets to flexible thin-film dosage forms. These films can be manufactured with precise dosing of active ingredients through techniques like hot-melt extrusion or spray drying, then cut into small, manageable sizes that are easy to swallow. The thin-film format maintains dosing accuracy through controlled manufacturing processes while achieving the small size needed for improved swallowability, particularly for pediatric and geriatric patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral film achieves precise and accurate active dissolution profiles with enhanced sampling points and rate of change evaluation, ensuring consistent drug delivery and compliance with regulatory standards.
Implementation Method 1
The film comprises: a water-soluble polymer matrix, a water swellable polymer matrix, or a water-soluble and water swellable polymer matrix
Implementation Method 2
The film comprises: a water-soluble polymer matrix, a water swellable polymer matrix, or a water-soluble and water swellable polymer matrix
Implementation Method 3
the absorption of drugs administered in the form of oral films depends on a number of factors, including the release of the drug substance from the film, the dissolution, and solubilization of the drug under physiological conditions
Data Source
AI summary
An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.